Table 1. Ongoing Phase II Clinical Trials of Neoadjuvant Immunotherapy and Radiotherapy in NSCLC.

	Eligible patients	Intervention	Estimated enrolment	Primary endpoint
NCT03237377	Resectable IIIA	Arm A: Durvalumab+Radiation (45 Gy/25 fx)→Surgery Arm B: Durvalumab+Tremelimumab+Radiation (45 Gy/25 fx)→Surgery	n=32	Toxicities and Feasibility
CHIO3 NCT04062708	Resectable IIIA/B	Platinum doublet×4 cycles+Durvalumab→Surgery±PORT (54Gy)+Durvalumab×13 cycles.	n=55	Nodal clearance
NCT03871153	Resectable III N2	Durvalumab+Paclitaxel+Carboplatin+RT (45–61.2 Gy)+Durvalumab→Surgery→Durvalumab	n=25	pCR
NCT02572843	Resectable IIIA N2	Cisplatin/Docetaxel×3 cycles→IT MEDI4736 (anti-PD-L1)→Surgery (±PORT) r IT MEDI4736 (anti-PD-L1)	n=68	EFS

PORT: Post-operative radiotherapy, pCR: Pathological complete response, EFS: Event-free survival, IT: Immunotherapy.